Akanda To Supply Tetra Bio-Pharma With Pharmaceutical-Grade Cannabis For FDA Trials Of QIXLEEF, A Potential Multimillion Dollar Prescription Drug
Akanda To Supply Tetra Bio-Pharma With Pharmaceutical-Grade Cannabis For FDA Trials Of QIXLEEF, A Potential Multimillion Dollar Prescription Drug
Provides Tetra with stable supply of high-quality ingredients and regulatory-approved services to satisfy clinical trials and prescription products
Diversifies Akanda into cancer pain medical market as a specialized manufacturer of cannabis-based drugs for use in FDA clinical trials and pharmaceutical markets
LONDON and MONTREAL, July 12, 2022 /PRNewswire/ - Akanda Corp. ("Akanda") (NASDAQ:AKAN) and Tetra Bio-Pharma ("Tetra") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), today jointly announced that Akanda will supply Tetra with pharmaceutical grade cannabis flower in a microdose cap form, for use in a Storz & Bickel Mighty Medic Vaporizer for global commercialization of Tetra's QIXLEEFTM and...
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧